Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Health Care Financ Rev ; 31(1): 51-61, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20191757

RESUMEN

CMS is investigating techniques that might help identify costly physician practice patterns. One method presently under evaluation is to compare resource use for certain episodes of care using commercially available episode grouping software. Although this software has been used by the private sector to classify insured individuals' medical claims into episodes of care, it has never been used with fee-for-service Medicare claims except in the studies by the Medicare Payment Advisory Commission (MedPAC) and CMS. This study reviews and reports on clinician feedback on the most obvious and important decisions that must be faced by Medicare to use grouped claims data as the foundation for a physician performance measurement system. The panel reactions show the importance of bringing persons with clinical knowledge into the development process. The clinician feedback confirms that additional research is needed.


Asunto(s)
Episodio de Atención , Retroalimentación , Revisión de Utilización de Seguros/organización & administración , Medicare , Pautas de la Práctica en Medicina/economía , Control de Costos/métodos , Humanos , Programas Informáticos , Estados Unidos
2.
World J Surg Oncol ; 6: 93, 2008 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-18764938

RESUMEN

BACKGROUND: Radiomicrosphere therapy (RT) utilizing yttrium-90 (90Y) microspheres has been shown to be an effective regional treatment for primary and secondary hepatic malignancies. We sought to determine a large academic institution's experience regarding the extent and frequency of gastrointestinal complications. METHODS: Between 2004 and 2007, 27 patients underwent RT for primary or secondary hepatic malignancies. Charts were subsequently reviewed to determine the incidence and severity of GI ulceration. RESULTS: Three patients presented with gastrointestinal bleeding and underwent upper endoscopy. Review of the pretreatment angiograms showed normal vascular anatomy in one patient, sclerosed hepatic vasculature in a patient who had undergone prior chemoembolization in a second, and an aberrant left hepatic artery in a third. None had undergone prophylactic gastroduodenal artery embolization. Endoscopic findings included erythema, mucosal erosions, and large gastric ulcers. Microspheres were visible on endoscopic biopsy. In two patients, gastric ulcers were persistent at the time of repeat endoscopy 1-4 months later despite proton pump inhibitor therapy. One elderly patient who refused surgical intervention died from recurrent hemorrhage. CONCLUSION: Gastrointestinal ulceration is a known yet rarely reported complication of 90Y microsphere embolization with potentially life-threatening consequences. Once diagnosed, refractory ulcers should be considered for aggressive surgical management.


Asunto(s)
Embolización Terapéutica/efectos adversos , Neoplasias Hepáticas/radioterapia , Radioterapia/efectos adversos , Úlcera Gástrica/etiología , Radioisótopos de Itrio/efectos adversos , Resultado Fatal , Femenino , Hemorragia Gastrointestinal/etiología , Humanos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Masculino , Microesferas , Estudios Retrospectivos , Úlcera Gástrica/diagnóstico
3.
Pharmacotherapy ; 26(7): 1018-22, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16803426

RESUMEN

Thalidomide is a relatively safe and efficacious form of therapy in the treatment of advanced, refractory multiple myeloma. Hepatotoxicity is listed as an extremely rare adverse effect associated with its use. We describe a 76-year-old woman with multiple myeloma who was treated with dexamethasone and thalidomide. By week 6 of therapy, she had developed acute increases in her aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels to more than 50 times the upper limit of normal. Her liver function test results had been within the normal ranges before and immediately after the start of therapy, and the patient had no known history of underlying liver disease. A liver biopsy specimen demonstrated evidence of acute injury with chronic changes of underlying steatosis and bridging fibrosis due to previously undiagnosed nonalcoholic steatohepatitis. Immediately after discontinuing thalidomide, her liver function test results began trending downward. Seven days later, her AST and ALT levels had improved to 86 and 165 U/L, respectively. This case and a limited number of other reports demonstrate severe hepatotoxicity as a rare but potentially serious adverse effect of thalidomide therapy. With the expanding use of thalidomide as a therapeutic agent, clinicians must recognize severe hepatotoxicity as a potential complication. Whether patients with preexisting liver disease are at increased risk when receiving thalidomide remains to be seen.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Talidomida/efectos adversos , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Biopsia , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Dexametasona/uso terapéutico , Femenino , Humanos , Pruebas de Función Hepática , Mieloma Múltiple/tratamiento farmacológico , Talidomida/uso terapéutico
4.
Gastroenterol Hepatol (N Y) ; 2(11): 806-807, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28381950
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA